Opus Genetics Inc. Ordinary Shares IRD 深 滬
已收盤 01-02 16:00:00 美东时间
2.12
+0.110
+5.47%
華盛通- 最 高2.33
- 今 開2.25
- 成交量 83.83万股
- 最 低 2.04
- 昨 收 2.01
- 總市值 1.46亿
- 52周最高 2.5907
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 0.65
- 委 比 -78.44%
- 總股本 6896.42万
- 歷史最高 23.08
- 量 比 3.40
- 振 幅 14.43%
- 歷史最低 0.65
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Opus Genetics Says IDMC Issues Positive Recommendation To Continue As Planned In Phase 1/2 BEST1 Clinical Trial, Evaluating Opgx-BEST1 In Participants With Best Disease
Opus Genetics (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases
2025-12-09 20:06
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Piper Sandler Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Biren Amin initiates coverage on Opus Genetics (NASDAQ:IRD) with a Overweight rating and announces Price Target of $7.
2025-11-25 22:27
Opus Genetics Q3 EPS $(0.25) Misses $(0.13) Estimate, Sales $3.079M Beat $3.075M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 13.79 percent increase over losses of $(0.29) per share from
2025-11-12 20:10
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Opus Genetics shares are trading lower after the company announced a $23 million registered direct offering.
Opus Genetics shares are trading lower after the company announced a $23 millio...
2025-11-07 00:04
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
2025-10-30 14:22
Wedbush Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $8
Wedbush analyst Yun Zhong initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $8.
2025-10-29 20:26
